23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      What Is the most Important for Elite Control: Genetic Background of Patient, Genetic Background of Partner, both or neither? Description of Complete Natural History within a Couple of MSM

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          We describe a homosexual man who strongly controlled HIV-1 for ten years despite lack of protective genetic background.

          Methods

          HIV-1 DNA was measured in blood and other tissues. Cell susceptibility was evaluated with various strains. HIV-1-specific (CD4 and CD8 activation markers and immune check points) and NK cells responses were assessed; KIRs haplotypes and HLA alleles were determined.

          Findings

          Two HIV-1 RNA copies/mL of plasma were detected in 2009, using an ultra-sensitive assay. HIV-DNA was detected at 1.1 and 2 copies/10 6 PBMCs in 2009 and 2015 respectively, at 1.2 copies/10 6 cells in rectal cells in 2011. WBs showed weak reactivity with antibodies to gp160, p55 and p25 from 2007 to 2014, remaining incomplete in 2017. CD4 T cells were susceptible to various strains including HIV KON, a primary isolate of his own CRF02_AG variant. CD8 T cells showed a strong poly-functional response against HIV-Gag, producing mainly IFN-γ; a robust capacity of antibody-dependant cell cytotoxicity (ADCC) was observed in NK cells. Case patient was group B KIR haplotype. Neutralizing antibodies were not detected. CD4 and CD8 blood T cells showed normal proportions without increased activation markers. Phylogenetic analyses identified the same CRF02_AG variant in his partner. The patient and his partner were heterozygous for the CCR5ΔD32 deletion and shared HLA-B*07, C*07 non-protective alleles.

          Interpretation

          This thorough description of the natural history of an individual controlling HIV-1 in various compartments for ten years despite lack of protective alleles, and of his partner, may have implications for strategies to cure HIV-1 infection.

          Highlights

          • We described a MSM, elite controller despite pejorative genetic background.

          • The patient had two HLA pejoratives alleles and no protective alleles.

          • The partner was infected by the same strain.

          • The genetic backgrounds of the patient and partner, and the virus could interact with each other to lead to elite control.

          We considered all the evidence about elite control, HLA, ADCC and NK, using Medline/PubMed. We described a MSM, elite controller despite non-protective genetic background, explored extensively the patient: sequential WBs, RNA in plasma (ultrasensitive assay), DNA in PBMC/GALT, cell susceptibility, HIV-1 responses in PBMC/LNMC, neutralizing antibodies, CD3-CD56 + NK, ADCC, KIRs. He had one HLA pejorative and no protective alleles. The partner was infected by the same strain, his genetic background was studied. The genetic background of the exposed person, of the source, and the viral strain could interact with each other to lead to elite control.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

          A selective advantage against infectious disease associated with increased heterozygosity at the human major histocompatibility complex [human leukocyte antigen (HLA) class I and class II] is believed to play a major role in maintaining the extraordinary allelic diversity of these genes. Maximum HLA heterozygosity of class I loci (A, B, and C) delayed acquired immunodeficiency syndrome (AIDS) onset among patients infected with human immunodeficiency virus-type 1 (HIV-1), whereas individuals who were homozygous for one or more loci progressed rapidly to AIDS and death. The HLA class I alleles B*35 and Cw*04 were consistently associated with rapid development of AIDS-defining conditions in Caucasians. The extended survival of 28 to 40 percent of HIV-1-infected Caucasian patients who avoided AIDS for ten or more years can be attributed to their being fully heterozygous at HLA class I loci, to their lacking the AIDS-associated alleles B*35 and Cw*04, or to both.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients.

            Natural killer (NK) cells are affected by infection with human cytomegalovirus (HCMV) manifested by increased expression of the HLA-E binding activating receptor NKG2C. We here show that HCMV seropositivity was associated with a profound expansion of NKG2C(+) CD56(dim) NK cells in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Multi-color flow cytometry revealed that the expanded NKG2C(+) CD56(dim) NK cells displayed a highly differentiated phenotype, expressed high amounts of granzyme B and exhibited polyfunctional responses (CD107a, IFN-γ, and TNF-α) to stimulation with antibody-coated as well as HLA-E expressing target cells but not when stimulated with IL-12/IL-18. More importantly, NKG2C(+) CD56(dim) NK cells had a clonal expression pattern of inhibitory killer cell immunoglobulin-like receptors (KIRs) specific for self-HLA class I molecules, with predominant usage of KIR2DL2/3. KIR engagement dampened NKG2C-mediated activation suggesting that such biased expression of self-specific KIRs may preserve self-tolerance and limit immune-pathology during viral infection. Together, these findings shed new light on how the human NK-cell compartment adjusts to HCMV infection resulting in clonal expansion and differentiation of educated and polyfunctional NK cells. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients.

              In healthy blood donors, serological positivity for human cytomegalovirus (HCMV) is associated with an increased proportion of NK cells bearing the CD94/NKG2C NK cell receptor (NKR). The expression of the activating CD94/NKG2C NKR and of the inhibitory CD94/NKG2A NKR was studied in a cohort of 45 aviremic human immunodeficiency virus type 1 (HIV-1)-positive patients receiving highly active antiretroviral therapy. The proportions of NKG2C+ NK cells were significantly increased in HIV-1-positive patients (mean +/- SD, 25.9% +/- 23.0%), compared with those in 31 healthy individuals (mean +/- SD, 16.1% +/- 20.7%). Yet, the association vanished when HCMV serological status was considered in a multivariate regression model. These results support the conclusion that changes in the NKR repertoire in HIV1-positive patients are related to a concomitant HCMV infection.
                Bookmark

                Author and article information

                Contributors
                Journal
                EBioMedicine
                EBioMedicine
                EBioMedicine
                Elsevier
                2352-3964
                07 December 2017
                January 2018
                07 December 2017
                : 27
                : 51-60
                Affiliations
                [a ]Département de Médecine Interne, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France
                [b ]U1135, CIMI, INSERM, Paris, France
                [c ]Sorbonne Universités, UPMC Université Paris 06, Paris, France
                [d ]EA7327, Faculté de Médecine, Université Paris-Descartes, Sorbonne Paris Cité, France
                [e ]Laboratoire de Virologie, Hôpital Necker-Enfants Malades, APHP, Paris, France
                [f ]Département d'Immunologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
                [g ]Laboratoire de Virologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
                [h ]CIRI, INSERM U1111, CNRS UMR5308, Université Lyon 1, ENS de Lyon, Lyon, France
                [i ]Service de Chirurgie Digestive et Cancérologique, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France
                [j ]Service de Gastroentérologie, Groupe Hospitalier Saint-Louis-Lariboisière-Fernand Widal, APHP, Paris, France.
                [k ]Normandie Univ, UNIROUEN, EA 2656, Rouen University Hospital, Department of Virology, F-76000 Rouen, France
                [l ]CNRS ERL8255, Centre, d'Immunologie et de Maladies Infectieuses (CIMI-Paris), Paris, France.
                [m ]Inserm U966 & National Reference Center for HIV, Université François-Rabelais & CHU Bretonneau, Tours, France
                [n ]Laboratoire de Virologie, Hôpital de la Croix-Rousse, Lyon, France
                [o ]INSERMU 965, Angiogenèse et recherche translationnelle, Paris 7, France
                Author notes
                [* ]Corresponding author: Département de Médecine Interne, GH Saint-Louis-Lariboisière-Fernand Widal, 2, rue Ambroise Paré, 75475 Paris Cedex 10, FranceDépartement de Médecine InterneGH Saint-Louis-Lariboisière-Fernand Widal2, rue Ambroise ParéParis Cedex 1075475France pierre.sellier@ 123456aphp.fr
                [1]

                The authors contributed equally to the work.

                [2]

                The authors contributed equally to the work.

                [3]

                Present address: Institut Mondor de Recherche biomédicale, Inserm U955, labex VRI (Vaccine Research Institute), Créteil, France.

                [4]

                Present address: Service de Gastroentérologie, Hôpitaux Universitaires de l'Est Parisien, APHP, Paris, France.

                Article
                S2352-3964(17)30484-X
                10.1016/j.ebiom.2017.12.003
                5828297
                29273355
                f518fd0f-e6cc-4704-a9de-a90ede14ec0a
                © 2017 The Authors

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 19 July 2017
                : 23 November 2017
                : 5 December 2017
                Categories
                Research Paper

                hiv-1,elite control,incomplete western blot,hiv-1 dna,immune activation,hla b*07 c*07,partner

                Comments

                Comment on this article